human antibody anti-Respiratory Syncytial Virus (RSV)
Respiratory Syncytial Virus (RSV)
Description Virus that causes respiratory syncytial virus (RSV) infection
Structure Respiratory syncytial virus (RSV) is an enveloped, negative-sense, single-stranded RNA virus belonging to the genus Orthopneumovirus within the family Pneumoviridae. The virus possesses a lipid envelope containing fusion (F) and attachment (G) glycoproteins that mediate viral entry into host cells and promote the formation of multinucleated syncytia, a characteristic feature of RSV infection. RSV primarily infects epithelial cells lining the respiratory tract and is one of the leading causes of lower respiratory tract disease in infants and young children worldwide. The virus is highly contagious and spreads through respiratory droplets, direct contact, and contaminated surfaces. Reinfections are common throughout life because immunity following natural infection is incomplete.
Diagnosis The diagnosis of RSV infection is performed through the detection of viral antigens, viral RNA, or RSV-specific antibodies. Molecular methods such as reverse transcription polymerase chain reaction (RT-PCR) are considered the most sensitive and specific diagnostic tests and are widely used in clinical laboratories. Rapid antigen detection assays and immunofluorescence tests may provide faster results but generally have lower sensitivity, particularly in adults. Serological assays, including ELISA-based methods, may be used in epidemiological studies or for the assessment of immune responses. Laboratory confirmation is particularly important in infants, elderly individuals, immunocompromised patients, and hospitalized patients with severe respiratory disease.
Symptoms Respiratory syncytial virus is a major cause of upper and lower respiratory tract infections. Following an incubation period of approximately two to eight days, infected individuals typically develop symptoms including nasal congestion, runny nose, cough, sneezing, low-grade fever, and reduced appetite. In infants and young children, RSV frequently progresses to bronchiolitis or pneumonia, characterized by wheezing, rapid breathing, respiratory distress, and decreased oxygen saturation. Premature infants, elderly individuals, and immunocompromised patients are at increased risk of severe disease and hospitalization. Although most infections are self-limiting, RSV remains a significant cause of morbidity and mortality worldwide, particularly among vulnerable populations.
Data
FAQ & Publications
Frequently Asked Questions
What is the intended application for the Respiratory Syncytial Virus IgA Control Serum BC113A?
The Respiratory Syncytial Virus IgA Control Serum BC113A is designed for use as an IgA control serum in ELISA applications, specifically compatible with SERION ELISA classic and SERION ELISA antigen assays.
How should the Respiratory Syncytial Virus IgA Control Serum BC113A be stored to maintain its stability?
This control serum should be stored refrigerated at 2-8°C to preserve its integrity and ensure reliable performance in downstream assays.
Publications
pmid
title
authors
citation
We haven't added any publications to our database yet.
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.
Reviews
There are no reviews yet.